Skip to main content
. 2023 Sep 29;15(19):4789. doi: 10.3390/cancers15194789

Figure 5.

Figure 5

Forest plot of hazard ratios (HR) for predicting progression free survival (PFS) and overall survival (OS) for pembrolizumab by individual and combined PD-L1 marker status for IHC and RNA-seq. Cox proportional regression analyses adjusted for potential covariates: age, sex, histologic subtype, smoking history, weighted performance status, and pembrolizumab line of treatment.